OREANDA-NEWS. On October 329, 2007 Veropharm [RTS: VRPH, MICEX: VFRM] announced its preliminary sales and operational results for the first nine months of 2007 according to the management’s accounting report, reported the press-centre of Veropharm.

Sales
According to management’s estimates, Veropharm’s net sales totaled $92,9 mln* in the first nine months of 2007.

Sales of Veropharm’s finished goods increased 32% y-o-y, totaling $90,2 mln in the first nine months of 2007.

Sales of prescription drugs in this period totaled $49,9 mln, demonstrating a 39% y-o-y growth.  The percentage of prescription drugs in the total sales volume was 55.3%**.

Sales of traditional drugs totaled $15,1 mln, demonstrating a 33% y-o-y growth.  The percentage of traditional drugs in the total sales volume was 16,7%.

Sales of adhesive bandages totaled $17,5 mln, demonstrating a 15% y-o-y growth.  The percentage of adhesive bandages in the total sales volume was 19,4%.

Sales of non-prescription drugs totaled $7,7 mln, demonstrating a 31% y-o-y growth. The percentage of non-prescription drugs in the total sales volume was 8,6%.

Veropharm’s sales within the Federal Reimbursement Program (FRP) totaled $4,3 mln, or 5% of the company’s sales. In the same period in 2006, Veropharm’s sales within the program totaled $5,2 mln, or 8% of the company’s sales.

Veropharm’s sales in Russia accounted for 95,8% of the company’s sales in the first nine months of 2007.

Full report see here: http://www.pharmacychain366.com/news/2007/10/93/